Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
出版年份 2016 全文链接
标题
Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
作者
关键词
-
出版物
DIABETES-METABOLISM RESEARCH AND REVIEWS
Volume 32, Issue 8, Pages 776-790
出版商
Wiley
发表日期
2016-04-22
DOI
10.1002/dmrr.2810
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events
- (2016) Keith C. Ferdinand et al. Cardiovascular Diabetology
- Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide
- (2016) Z. Milicevic et al. DIABETES OBESITY & METABOLISM
- Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
- (2015) Francesco Giorgino et al. DIABETES CARE
- Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study
- (2015) R. S. Weinstock et al. DIABETES OBESITY & METABOLISM
- Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
- (2015) Lawrence Blonde et al. LANCET
- Albiglutide
- (2014) Jennifer M. Trujillo et al. ANNALS OF PHARMACOTHERAPY
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Introduction
- (2014) DIABETES CARE
- Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)
- (2014) Guillermo Umpierrez et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
- (2014) Carol Wysham et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
- (2014) Michael Nauck et al. DIABETES CARE
- Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5)
- (2014) Z. Skrivanek et al. DIABETES OBESITY & METABOLISM
- Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study
- (2014) Yasuo Terauchi et al. ENDOCRINE JOURNAL
- Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus
- (2014) Keith C. Ferdinand et al. HYPERTENSION
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- (2014) Kathleen M Dungan et al. LANCET
- Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes
- (2014) Louis Kuritzky et al. POSTGRADUATE MEDICINE
- Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
- (2014) Philip Raskin et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
- (2014) Gian Paolo Fadini et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- A practice-based approach to the 2012 position statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2013) Stanley S. Schwartz CURRENT MEDICAL RESEARCH AND OPINION
- Incretin dysfunction in type 2 diabetes: Clinical impact and future perspectives
- (2013) B. Ahrén DIABETES & METABOLISM
- Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
- (2013) R. A. DeFronzo et al. DIABETES CARE
- American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement - Executive Summary
- (2013) Alan Garber et al. Endocrine Practice
- Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
- (2013) L van Bloemendaal et al. JOURNAL OF ENDOCRINOLOGY
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
- (2013) Louise E Robinson et al. BMJ Open
- Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets
- (2012) J. H. DeVries et al. DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study
- (2012) G. Grunberger et al. DIABETIC MEDICINE
- Elevated Amylase and Lipase Levels in Patients Using Glucagonlike Peptide-1 Receptor Agonists or Dipeptidyl-Peptidase-4 Inhibitors in the Outpatient Setting
- (2012) Howard Lando et al. Endocrine Practice
- Drug-induced hypoglycaemia in type 2 diabetes
- (2012) Berit Inkster et al. Expert Opinion On Drug Safety
- Liraglutide-Induced Acute Kidney Injury
- (2012) Yaman Kaakeh et al. PHARMACOTHERAPY
- Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
- (2011) J. J. Holst et al. DIABETES CARE
- LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects
- (2011) P. Barrington et al. DIABETES OBESITY & METABOLISM
- The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study
- (2011) G. E. Umpierrez et al. DIABETES OBESITY & METABOLISM
- A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes
- (2011) P. Barrington et al. DIABETES OBESITY & METABOLISM
- DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
- (2011) Thomas Blevins et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein
- (2010) Wolfgang Glaesner et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
- (2010) Michaela Diamant et al. LANCET
- Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers
- (2010) Alfonso López-Ruiz et al. PHARMACY WORLD & SCIENCE
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- Exenatide-Associated Ischemic Renal Failure
- (2009) W. J. Weise et al. DIABETES CARE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now